“…Formal analyses of a theoretical mineral oil effect evaluated during an FDA Advisory Committee showed that hsCRP changes had little to no impact on the primary and secondary composite endpoints of REDUCE-IT ( Figure 2 , Supplementary material online , Table S1 ). 16 Inconsistent increases and decreases in other inflammatory markers across a range of conditions, including interleukin (IL)-6, 56 , 62 , 66 , 69 , 70 IL-1β, 56 , 61 , 70 , 71 IL-10, 69 tumour necrosis factor-α, 37 , 56 , 61 , 69 , 70 , 72 intercellular adhesion molecule 1, 62 monocyte chemoattractant protein-1, 71 and immunoglobulin E 52 have been reported. However, these changes have been small and in general, the clinical significance of hsCRP changes in CV outcome trials is unclear.…”